"Today's biotech companies must deftly navigate parallel routes to liquidity and fundraising. Private biotech companies must have a diverse playbook for funding product development efforts and achieving liquidity that includes running multiple types of transaction options concurrently. Panelists will share their perspectives on the market dynamics driving private biotech companies to pursue parallel opportunities, effective strategies for executing these diverse transactions concurrently and lessons learned from their experiences advising or managing private biotech companies."

Objective1: Encourage thinking strategically about approach to fundraising and deal execution in view of current market dynamics.

Objective2: Provide a framework for structuring and executing plans to conduct concurrent fundraising and deal negotiations.

Objective3: Enable biotech executives to identify which of several competitive strategies may be appropriate for their company in the next few years.